PT Indofarma Tbk

IDX:INAF Stock Report

Market Cap: Rp390.5b

Indofarma Past Earnings Performance

Past criteria checks 0/6

Indofarma's earnings have been declining at an average annual rate of -70.1%, while the Pharmaceuticals industry saw earnings growing at 16.4% annually. Revenues have been declining at an average rate of 14.1% per year.

Key information

-70.1%

Earnings growth rate

-70.0%

EPS growth rate

Pharmaceuticals Industry Growth20.4%
Revenue growth rate-14.1%
Return on equityn/a
Net Margin-260.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Indofarma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

IDX:INAF Revenue, expenses and earnings (IDR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24269,352-702,586171,8360
31 Mar 24397,441-713,140201,6900
31 Dec 23523,599-720,993216,1300
30 Sep 23684,913-437,053238,9550
30 Jun 23770,282-487,255250,0790
31 Mar 23811,139-468,238247,5710
31 Dec 22980,371-457,624266,3720
30 Sep 222,309,033-223,515273,0860
30 Jun 222,626,715-129,273272,8900
31 Mar 222,867,810-90,583292,2020
31 Dec 212,901,987-37,581292,7880
30 Sep 212,464,18421,734310,1900
30 Jun 212,117,6145,667309,1150
31 Mar 211,940,62523,276284,5350
31 Dec 201,715,58828261,2740
30 Sep 201,524,89323,922213,9230
30 Jun 201,437,66127,656211,4740
31 Mar 201,371,0768,304212,7230
31 Dec 191,359,1757,961225,4720
30 Sep 191,437,345-32,484259,1590
30 Jun 191,542,508-57,346271,6840
31 Mar 191,580,299-46,023275,5580
31 Dec 181,592,980-32,736274,7540
30 Sep 181,594,144-17,230266,8980
30 Jun 181,569,3817,510253,0950
31 Mar 181,572,352-19,937253,2800
31 Dec 171,631,317-46,283270,5450
30 Sep 171,582,421-51,107267,7820
30 Jun 171,684,605-43,041284,2810
31 Mar 171,681,116-32,623302,8140
31 Dec 161,674,703-17,367289,9520
30 Sep 161,695,1048,132274,9590
30 Jun 161,630,4392,507266,9380
31 Mar 161,628,6696,937259,6950
31 Dec 151,621,8996,567266,3640
30 Sep 151,384,0225,140263,3420
30 Jun 151,456,52228,537259,4450
31 Mar 151,421,09219,882257,8560
31 Dec 141,381,4371,442269,1990
30 Sep 141,489,448-28,726327,4360
30 Jun 141,378,964-95,824373,7440
31 Mar 141,369,123-81,641373,5660
31 Dec 131,337,498-54,222348,6900
30 Sep 131,095,394-38,816309,7130

Quality Earnings: INAF is currently unprofitable.

Growing Profit Margin: INAF is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: INAF is unprofitable, and losses have increased over the past 5 years at a rate of 70.1% per year.

Accelerating Growth: Unable to compare INAF's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INAF is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).

Return on Equity

High ROE: INAF's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/28 17:06
End of Day Share Price 2024/07/01 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PT Indofarma Tbk is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yohan SetioPT Mandiri Sekuritas
Guntur HariyantoPT PEFINDO